DeSoto Peptides Research Journal | October 2026
Mitochondria are essential to cellular metabolism, but their functions extend far beyond generating energy.
They also regulate signaling pathways, respond to changes in nutrient availability, participate in cellular stress responses, and maintain specialized membrane structures necessary for normal biological activity.
Two compounds that have attracted scientific attention in mitochondrial research are MOTS-C and SS-31, also known as elamipretide.
Although both are associated with mitochondrial biology, they differ substantially in molecular origin, mechanism of action, and clinical evidence.
MOTS-C is a mitochondrial-encoded peptide investigated for its relationship with metabolic signaling and cellular energy sensing.
SS-31 is a synthetic peptide investigated for its interaction with cardiolipin, a specialized lipid found primarily in the inner mitochondrial membrane.
These differences highlight an important scientific distinction:
Regulating cellular metabolic responses and influencing mitochondrial membrane function are related, but separate biological processes.
Understanding Mitochondrial Structure and Function
Mitochondria contain several specialized structures.
Two particularly important components are the outer and inner mitochondrial membranes.
The inner mitochondrial membrane contains many of the protein complexes involved in oxidative phosphorylation.
This process uses energy derived from electron transfer to support ATP production.
The membrane is also folded into structures known as cristae.
Cristae increase the surface area available for respiratory machinery and play important roles in mitochondrial organization.
Why Mitochondrial Membranes Matter
The inner mitochondrial membrane supports several important processes:
Electron transport
Proton-gradient formation
ATP synthesis
Organization of respiratory complexes
Regulation of mitochondrial structure
Maintenance of cellular energy metabolism
Disruption of these systems can influence mitochondrial function.
However, mitochondrial dysfunction is not one single disease or biological condition.
Different disorders and physiological stresses can affect different components of the mitochondrial system.
This complexity is central to understanding why MOTS-C and SS-31 have different research applications.
What Is MOTS-C?
MOTS-C is a naturally occurring 16-amino-acid peptide encoded by mitochondrial DNA.
Its name refers to the mitochondrial open reading frame of the 12S rRNA type-c.
MOTS-C belongs to a class of molecules called mitochondrial-derived peptides.
These molecules have attracted interest because they demonstrate that mitochondria can participate directly in cellular communication.
MOTS-C has been investigated primarily for its relationships with:
Cellular metabolic signaling
AMPK activity
Glucose utilization
Insulin sensitivity
Metabolic stress responses
Skeletal muscle metabolism
Mitochondrial-to-nuclear communication
Its research emphasizes how cells respond to changing energy conditions.
MOTS-C and the AMPK Pathway
One of the most significant areas of MOTS-C research involves AMP-activated protein kinase, or AMPK.
AMPK is an energy-sensing enzyme that helps coordinate cellular responses to changes in energy availability.
It participates in processes involving glucose metabolism, fatty acid utilization, and cellular responses to energetic stress.
The 2015 Discovery Study
A landmark study published in Cell Metabolism identified MOTS-C as a mitochondrial-derived peptide associated with metabolic homeostasis.
Researchers found that MOTS-C influenced folate metabolism and purine biosynthesis in experimental systems.
These changes were associated with AMPK activation.
The investigators also reported protection against certain forms of insulin resistance and diet-associated obesity in mouse models.
These findings established MOTS-C as an important molecule for investigating metabolic signaling.
However, the results did not establish equivalent effects from administered MOTS-C in humans.
View the Original MOTS-C Study
MOTS-C and Mitochondrial-to-Nuclear Communication
A 2018 study published in Cell Metabolism investigated how MOTS-C participates in communication between mitochondria and the cell nucleus.
Researchers observed that MOTS-C could move into the nucleus under certain metabolic stress conditions.
This process was associated with AMPK-dependent signaling.
Within the nucleus, MOTS-C influenced gene-expression pathways associated with cellular stress responses.
The findings suggested that mitochondrial-derived peptides may contribute to regulation of nuclear gene activity.
This is significant because mitochondria possess their own genetic material, while many proteins necessary for mitochondrial function are encoded by nuclear DNA.
Communication between these systems is essential for coordinated cellular activity.
MOTS-C provides an experimental model for studying this relationship.
View the Published Cellular Signaling Study
MOTS-C and Exercise Research
MOTS-C has also been investigated in relation to physical activity.
A 2021 study published in Nature Communications examined MOTS-C in humans and mice.
Researchers observed increases in naturally occurring MOTS-C in human muscle and circulation following exercise.
The study also reported improved measures of physical performance in mice following experimental administration of MOTS-C.
These findings generated interest in its relationship with exercise-related metabolic signaling.
However, the human findings involved naturally occurring MOTS-C responses during physical activity.
The administration experiments demonstrating physical-performance changes were conducted in mice.
The study did not establish that administering MOTS-C improves human exercise performance.
View the MOTS-C Exercise Study
What Is SS-31?
SS-31, also known as elamipretide, is a synthetic mitochondria-targeting tetrapeptide.
It was investigated for its interaction with components of the inner mitochondrial membrane, particularly cardiolipin.
Unlike MOTS-C, SS-31 is not a naturally encoded mitochondrial signaling peptide.
Instead, it is a synthetic compound developed to investigate mitochondrial membrane-associated processes.
What Is Cardiolipin?
Cardiolipin is a specialized phospholipid particularly abundant in the inner mitochondrial membrane.
It contributes to several important aspects of mitochondrial function, including:
Membrane organization
Respiratory complex interactions
Cristae structure
Mitochondrial protein function
Electron transport efficiency
Cardiolipin has a distinctive chemical structure that helps it interact with mitochondrial proteins.
Changes in cardiolipin composition or organization can affect mitochondrial processes.
These relationships have made cardiolipin an important subject of research into mitochondrial disease.
How SS-31 Interacts With Cardiolipin
SS-31 has been investigated for its ability to associate with cardiolipin-containing mitochondrial membranes.
Experimental studies suggest that this interaction can influence membrane-associated processes and mitochondrial protein organization.
Research has examined potential effects on:
Respiratory chain function
Mitochondrial membrane organization
Oxidative stress-related processes
Energy metabolism
Mitochondrial structure
The proposed mechanism differs from MOTS-C's relationship with AMPK-associated metabolic signaling.
SS-31 research focuses more directly on membrane-related mitochondrial biology.
However, biological activity in experimental systems does not guarantee improvements in every mitochondrial condition.
Different disorders involve different mechanisms, and clinical outcomes must be demonstrated directly.
MOTS-C vs. SS-31: The Main Scientific Differences
Research characteristicMOTS-CSS-31 / ElamipretideMolecular classificationMitochondrial-encoded peptideSynthetic tetrapeptidePrimary research areaMetabolic signalingMitochondrial membrane biologyMajor associated mechanismAMPK-related signalingCardiolipin-associated interactionsResearch emphasisCellular adaptation to metabolic stressInner mitochondrial membrane functionHuman evidenceExercise-related endogenous observationsClinical trials in mitochondrial disordersClinical developmentInvestigationalApproved formulation for a specific rare diseaseGeneral anti-aging benefit establishedNoNo
The distinction is not simply that one compound affects metabolism and the other affects mitochondria.
Both are relevant to mitochondrial biology.
The difference lies in the specific mechanisms and research questions being investigated.
Why Are MOTS-C and SS-31 Discussed Together?
Interest in MOTS-C and SS-31 arises from the relationship between mitochondrial function and cellular metabolic regulation.
Mitochondria require appropriately organized membranes and functioning respiratory machinery to support energy metabolism.
Cells also need signaling systems that coordinate their responses to changing energy demands.
MOTS-C and SS-31 represent different approaches to investigating these two aspects of mitochondrial biology.
MOTS-C: Metabolic Communication
MOTS-C research emphasizes mitochondrial-derived signaling and cellular adaptation.
Its association with AMPK helps explain why it has attracted interest in metabolic stress and exercise research.
SS-31: Mitochondrial Membrane Biology
SS-31 research emphasizes interactions with the inner mitochondrial membrane and cardiolipin.
Its development has focused on whether these interactions can produce meaningful improvements in specific mitochondrial disorders.
The Scientific Connection
Both research pathways relate to cellular energy regulation.
However, there is no established clinical evidence demonstrating that administering SS-31 before MOTS-C is necessary, improves outcomes, or creates a validated combination protocol.
The idea that mitochondrial membrane function and metabolic signaling could interact is biologically reasonable.
But a proposed relationship does not establish clinical synergy.
SS-31 and Human Clinical Trials
One important distinction between MOTS-C and SS-31 is the extent of human clinical investigation.
Elamipretide has undergone clinical research in several mitochondrial-related conditions.
These studies have evaluated outcomes such as physical functioning, fatigue, cardiovascular measurements, and disease-specific markers.
Primary Mitochondrial Myopathy Research
A Phase 3 clinical trial known as MMPOWER-3 examined elamipretide in patients with primary mitochondrial myopathy.
The trial investigated outcomes including six-minute walking distance and fatigue.
The study did not demonstrate statistically significant improvements in its primary efficacy endpoints compared with placebo.
These findings illustrated the challenge of translating promising mitochondrial mechanisms into measurable clinical benefits.
Mitochondrial diseases are heterogeneous, and improvements in experimental measures do not always translate into improved patient outcomes.
SS-31 and Barth Syndrome
Barth syndrome is a rare inherited disorder associated with abnormalities in cardiolipin remodeling.
It can affect cardiac and skeletal muscle function and several other biological systems.
Because cardiolipin is central to the disorder, Barth syndrome became an important clinical research target for elamipretide.
FDA Accelerated Approval in 2025
On September 19, 2025, the U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide).
The approval covers treatment of Barth syndrome in patients weighing at least 30 kilograms.
This was the first FDA-approved treatment specifically for Barth syndrome.
The approval is particularly significant because it demonstrates that a compound targeting mitochondrial biology can progress through clinical development for a defined indication.
However, accelerated approval for Barth syndrome does not establish elamipretide as a general mitochondrial enhancer, anti-aging treatment, or athletic performance compound.
It also does not establish that independently sourced SS-31 research materials are equivalent to the approved prescription formulation.
View FDA Approval Announcement
What Does FDA Accelerated Approval Mean?
Accelerated approval is a regulatory pathway that allows approval based on an endpoint reasonably likely to predict clinical benefit in serious conditions with unmet medical needs.
Additional studies may be required to verify and describe the anticipated clinical benefit.
The pathway differs from demonstrating that every proposed use has been established through long-term clinical outcomes.
For elamipretide, approval relates to a specific formulation and patient population.
It should not be generalized to unrelated mitochondrial disorders or general wellness applications.
Why Mitochondrial Research Cannot Be Reduced to ATP Production
A common oversimplification is that any compound affecting mitochondria must directly increase energy levels.
Mitochondrial biology involves numerous interacting systems.
These include:
Respiratory complex organization
Electron transport
ATP synthesis
Membrane structure
Reactive oxygen species signaling
Calcium regulation
Cellular stress responses
Metabolite exchange
Communication with the nucleus
Different compounds may influence different parts of these processes.
An improvement in one cellular measurement does not necessarily indicate improved overall mitochondrial function.
Likewise, improvements in mitochondrial function do not automatically establish greater endurance, recovery, or longevity.
Clinical measurements are necessary to evaluate outcomes in humans.
MOTS-C, SS-31, and Aging Research
Aging-related research has increasingly examined mitochondrial biology.
Scientists are investigating changes in respiratory function, mitochondrial communication, membrane organization, and cellular responses to metabolic stress.
MOTS-C and SS-31 are relevant to different areas of these investigations.
MOTS-C has been studied in connection with age-associated changes in metabolism and physical function in experimental systems.
SS-31 has been investigated for mitochondrial membrane-related mechanisms and clinical outcomes in selected disease populations.
However, neither compound has been demonstrated to reverse normal human aging or extend human lifespan.
The relevance of mitochondrial pathways to aging does not establish that manipulating those pathways produces a clinically meaningful anti-aging effect.
Why Formulation and Molecular Identity Matter
MOTS-C and SS-31 are different peptides with different molecular structures.
Their identity must be established accurately when evaluating experimental results.
Relevant analytical documentation may include:
Exact peptide sequence
Molecular identity
Lot or batch identification
Purity analysis
Quantitative content
Testing date
Relevant stability information
Chemical purity alone does not establish sterility, pharmacological equivalence, or clinical suitability.
This is especially relevant when comparing research materials with products investigated in formal clinical trials.
Frequently Asked Questions About MOTS-C and SS-31
Is MOTS-C the Same as SS-31?
No. MOTS-C is a mitochondrial-encoded signaling peptide, while SS-31 is a synthetic tetrapeptide investigated for cardiolipin-associated mitochondrial membrane interactions.
Does MOTS-C Activate AMPK?
Experimental research has linked MOTS-C activity with AMPK-associated signaling. These findings do not establish a universal response to administered MOTS-C in humans.
What Is Cardiolipin?
Cardiolipin is a specialized lipid associated with the inner mitochondrial membrane. It helps organize membrane proteins and supports aspects of mitochondrial function.
Is SS-31 FDA-Approved?
An elamipretide prescription formulation, Forzinity, received FDA accelerated approval in September 2025 for Barth syndrome in patients weighing at least 30 kilograms.
That approval does not extend to all SS-31 materials or uses.
Is MOTS-C FDA-Approved?
No. MOTS-C remains investigational and is not FDA-approved as a human therapeutic medication.
Does SS-31 Need to Be Used Before MOTS-C?
There is no established clinical evidence demonstrating that SS-31 must precede MOTS-C or that sequential administration provides additional benefits.
Do MOTS-C and SS-31 Improve Athletic Performance?
MOTS-C administration improved some physical-performance measures in experimental mice.
Elamipretide has undergone human clinical trials for specific diseases.
These findings do not establish that combining the compounds improves athletic performance in healthy people.
Are MOTS-C and SS-31 Proven Anti-Aging Peptides?
No. Their mechanisms are scientifically relevant to research involving aging-related biological processes, but clinical evidence does not establish that either reverses normal human aging.
Final Thoughts: Two Different Approaches to Mitochondrial Biology
MOTS-C and SS-31 represent distinct areas of modern mitochondrial research.
MOTS-C provides a model for investigating mitochondrial-derived signaling, AMPK activity, and cellular responses to metabolic stress.
SS-31 has been investigated for its interactions with cardiolipin and mitochondrial membrane-related processes.
The differences in clinical development are also important.
MOTS-C remains primarily supported by experimental research and observations of naturally occurring peptide responses.
Elamipretide has undergone human clinical development and received accelerated approval for a defined rare mitochondrial disorder.
Understanding these differences provides a more useful foundation for mitochondrial research than assuming every mitochondria-related compound produces the same biological effects.
Future studies may clarify how mitochondrial membrane organization and metabolic communication interact, but the clinical benefits of combining MOTS-C and SS-31 remain unestablished.
Published Scientific Research and References
Lee C, et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism.
Kim KH, et al. (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism.
Reynolds JC, et al. (2021). MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis. Nature Communications.
U.S. Food and Drug Administration (2025). FDA Grants Accelerated Approval to First Treatment for Barth Syndrome.
Cardiolipin Remodelling in Mitochondrial Therapeutics: Translational Evidence Chains From Elamipretide to Emerging Strategies (2026).
Research Disclaimer: This article is published by DeSoto Peptides for educational and scientific purposes. MOTS-C is investigational. An approved elamipretide formulation exists for a specific indication, but this does not establish the safety or equivalence of independently sourced research materials. This article does not recommend administering or combining these compounds and does not constitute medical advice.